Community Trust & Investment Co. Acquires 829 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Community Trust & Investment Co. increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,606 shares of the medical research company’s stock after acquiring an additional 829 shares during the period. Community Trust & Investment Co.’s holdings in IQVIA were worth $17,442,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of IQV. Ballentine Partners LLC boosted its position in IQVIA by 11.8% in the 1st quarter. Ballentine Partners LLC now owns 1,424 shares of the medical research company’s stock valued at $360,000 after buying an additional 150 shares during the last quarter. Riverview Trust Co bought a new position in IQVIA in the 1st quarter valued at $32,000. Wealth Enhancement Advisory Services LLC boosted its position in shares of IQVIA by 5.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,898 shares of the medical research company’s stock worth $1,492,000 after purchasing an additional 300 shares during the last quarter. Cypress Wealth Services LLC boosted its position in shares of IQVIA by 5.3% in the 1st quarter. Cypress Wealth Services LLC now owns 1,101 shares of the medical research company’s stock worth $278,000 after purchasing an additional 55 shares during the last quarter. Finally, Sendero Wealth Management LLC boosted its position in shares of IQVIA by 0.7% in the 1st quarter. Sendero Wealth Management LLC now owns 33,122 shares of the medical research company’s stock worth $8,376,000 after purchasing an additional 229 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

Shares of NYSE IQV opened at $228.30 on Wednesday. The stock has a market capitalization of $41.62 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.26 and a beta of 1.49. The business has a 50-day moving average of $238.87 and a 200-day moving average of $230.93. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter last year, the company earned $2.22 EPS. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IQV. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada initiated coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Argus raised IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $267.87.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.